Dr. Bryan A. Sisk, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
1 Childrens Pl, Div Ped Hematology And Onc
Saint Louis, MO 63110
At a glance
- Medical school
- Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
MO license 2016010209 -
Pediatrics Physician
MO license 2016010209
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Vijoice (alpelisib) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 3 payments worth $2,401 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $2,401 |
|---|
| Consulting Fee | $2,240 |
|---|---|
| Food and Beverage | $161 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation May 7, 2025 | Consulting Fee VIJOICE · Oncology | $2,240 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $1,175,237 in research payments for these studies, mostly to the institutions running them.
- EPIK-L1: a phase II/III double-blind, randomized, placebo-controlled study to assess the efficacy, safety and pharmacokinetics of alpelisib in pediatric and adult patients with lymphatic malformations associated with …
Novartis Pharmaceuticals Corporation - EPIK-P2: A Phase II Double-blind Study With an Upfront, 16-week Randomized, Placebo-controlled Period, to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.